Syndax Pharmaceuticals Files Q1 2025 10-Q
Ticker: SNDX · Form: 10-Q · Filed: May 5, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 10-Q |
| Filed Date | May 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Syndax Pharma's Q1 2025 10-Q is in, check out their UCB Biopharma deal and stock info.
AI Summary
Syndax Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including information related to its UCB Biopharma license agreement and various stock plans. The company's fiscal year ends on December 31st.
Why It Matters
This filing provides investors with the latest financial health and operational status of Syndax Pharmaceuticals, crucial for understanding its ongoing drug development and business strategy.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Syndax faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Syndax Pharmaceuticals Inc (company) — Filer of the 10-Q
- UCB Biopharma (company) — Party to a license agreement with Syndax
- March 31, 2025 (date) — End of the reporting period
- December 31 (date) — Fiscal year end
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When does Syndax Pharmaceuticals' fiscal year end?
Syndax Pharmaceuticals' fiscal year ends on December 31st.
What is the SEC file number for Syndax Pharmaceuticals?
The SEC file number for Syndax Pharmaceuticals is 001-37708.
What is the Central Index Key (CIK) for Syndax Pharmaceuticals?
The Central Index Key (CIK) for Syndax Pharmaceuticals is 0001395937.
What specific agreements or plans are mentioned in relation to Syndax Pharmaceuticals in the filing data?
The filing data mentions the UCB Biopharma license agreement, the TwoThousandTwentyThreeInducementIncentivePlan, and the Employee Stock Purchase Plan.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding Syndax Pharmaceuticals Inc (SNDX).